GEP20257803B - Treatment of headache using anti-cgrp antibodies - Google Patents

Treatment of headache using anti-cgrp antibodies

Info

Publication number
GEP20257803B
GEP20257803B GEAP202015803A GEAP2020015803A GEP20257803B GE P20257803 B GEP20257803 B GE P20257803B GE AP202015803 A GEAP202015803 A GE AP202015803A GE AP2020015803 A GEAP2020015803 A GE AP2020015803A GE P20257803 B GEP20257803 B GE P20257803B
Authority
GE
Georgia
Prior art keywords
treatment
headache
cgrp antibodies
cgrp
antibodies
Prior art date
Application number
GEAP202015803A
Other languages
English (en)
Inventor
Lahar Mehta
Roger K Cady
Jeffrey T L Smith
Joseph Hirman
Barbara Schaeffler
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/012781 external-priority patent/WO2020146527A1/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of GEP20257803B publication Critical patent/GEP20257803B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GEAP202015803A 2019-05-02 2020-02-18 Treatment of headache using anti-cgrp antibodies GEP20257803B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842162P 2019-05-02 2019-05-02
US201962872989P 2019-07-11 2019-07-11
PCT/US2020/012781 WO2020146527A1 (en) 2019-01-08 2020-01-08 Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Publications (1)

Publication Number Publication Date
GEP20257803B true GEP20257803B (en) 2025-10-10

Family

ID=73028680

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP202015803A GEP20257803B (en) 2019-05-02 2020-02-18 Treatment of headache using anti-cgrp antibodies
GEAP202515803A GEAP202515803A (en) 2019-05-02 2020-02-18 Treatment of headache using anti-cgrp antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP202515803A GEAP202515803A (en) 2019-05-02 2020-02-18 Treatment of headache using anti-cgrp antibodies

Country Status (20)

Country Link
US (1) US20220251178A1 (https=)
EP (1) EP3962522A4 (https=)
JP (2) JP2022533030A (https=)
KR (1) KR20220004053A (https=)
CN (1) CN113811326A (https=)
AU (1) AU2020267107B2 (https=)
BR (1) BR112020027063A2 (https=)
CA (1) CA3133571A1 (https=)
CL (1) CL2021002866A1 (https=)
DO (1) DOP2021000215A (https=)
EA (1) EA202192865A1 (https=)
GE (2) GEP20257803B (https=)
IL (1) IL287759A (https=)
JO (1) JOP20210247A1 (https=)
MA (1) MA55815A (https=)
MX (1) MX2021013426A (https=)
PH (1) PH12021552422A1 (https=)
SG (1) SG11202110637RA (https=)
WO (1) WO2020222892A1 (https=)
ZA (1) ZA202106627B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310885A (en) * 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
KR20240058082A (ko) 2021-09-15 2024-05-03 하. 룬드벡 아크티에셀스카브 항-cgrp 항체 투약 및 스크리닝 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827982B (zh) * 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
AU2015230933B2 (en) * 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
TWI799849B (zh) * 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
CN109952314A (zh) * 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
WO2020146527A1 (en) * 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Also Published As

Publication number Publication date
KR20220004053A (ko) 2022-01-11
MA55815A (fr) 2022-03-09
CL2021002866A1 (es) 2022-06-17
AU2020267107A1 (en) 2021-10-07
EP3962522A4 (en) 2023-07-19
BR112020027063A2 (pt) 2021-11-16
ZA202106627B (en) 2025-12-17
CA3133571A1 (en) 2020-11-05
IL287759A (en) 2022-01-01
JP2026016471A (ja) 2026-02-03
EA202192865A1 (ru) 2022-02-14
PH12021552422A1 (en) 2022-07-11
WO2020222892A1 (en) 2020-11-05
GEAP202515803A (en) 2025-06-10
EP3962522A1 (en) 2022-03-09
JOP20210247A1 (ar) 2023-01-30
JP2022533030A (ja) 2022-07-21
US20220251178A1 (en) 2022-08-11
CN113811326A (zh) 2021-12-17
MX2021013426A (es) 2021-12-10
SG11202110637RA (en) 2021-10-28
AU2020267107B2 (en) 2026-04-09
DOP2021000215A (es) 2021-11-21

Similar Documents

Publication Publication Date Title
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12019502283A1 (en) Anti-lag3 antibodies
ZA202201874B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
MY203971A (en) Anti-lag-3 antibodies and compositions
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2019009117A (es) Anticuerpos anti alfa-sinucleina y usos de los mismos.
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
ZA202005388B (en) Methods of treating ulcerative colitis
PH12018500578A1 (en) Methods of treating inflammatory diseases
PH12022551228A1 (en) Trem2 antibodies and uses thereof
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PH12020550023A1 (en) Compositions for treating stress-related disorders
PH12019502694A1 (en) Anti-trkb antibodies
ZA202006216B (en) Antibodies targeting glycoprotein vi
PH12017501872A1 (en) Methods of treating diseases
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
GEP20257803B (en) Treatment of headache using anti-cgrp antibodies
SA521431223B1 (ar) Angpt2 أجسام مضادة لـ
EA202092640A1 (ru) Способы и композиции для лечения хронической крапивницы
WO2020033925A3 (en) Antibodies that bind cd277 and uses thereof
MX2018003040A (es) Metodos para el tratamiento de formas recurrentes de esclerosis multiple.